Table of Content

1. Global Parkinson’s Disease Prevalence & Statistics
1.1 North America
1.1.1 United States
1.1.2 Canada
1.2 Europe
1.2.1 United Kingdom
1.2.2 Germany
1.2.3 Russia
1.3 Asia- Pacific
1.3.1 China
1.3.2 Japan
1.3.3 India
1.3.4 South Korea
1.3.5 Australia
1.3.6 New Zealand


2. Global Parkinson’s Drug Market Analysis
2.1 Current Market Scenario
2.2 Global Parkinson’s Drug Market Segmentation
2.2.1 Regional Segmentation
2.2.2 Segmentation by Products


3. Anti-Parkinson’s Drugs - Availability, Dosage & Price Analysis
3.1 Levodopa/Carbidopa Therapeutics
3.1.1 Duopa/Duodopa
3.1.2 Rytary
3.1.3 Sinemet
3.2 Dopamine Agonist
3.2.1 Rotigotine (Neupro)
3.2.2 Pramipexole
3.2.3 Ropinirole
3.3 MAO B Inhibitors
3.3.1 Selegiline
3.3.2 Safinamide (Xadago)
3.3.3 Rasagiline
3.4 Catechol O-methyltransferase (COMT) inhibitors
3.4.1 Entacapone
3.4.2 Tolcapone
3.5 Other Anti-Parkinson’s Drugs
3.5.1 Benztropine
3.5.2 Amantidine
3.5.3 Istradefylline (Nourianz)
3.5.4 Rivastigmine


4. Global Parkinson’s Drug Market Drivers


5. Challenges for Global Parkinson’s Drug Market


6. Global Parkinson’s Drug Market Future Outlook


7. Global Parkinson’s Disease Drug Clinical Pipeline Overview
7.1 By Phase
7.2 By Drug Class
7.3 By Mechanism of Action
7.4 By Formulation
7.5 By Country


8. Global Parkinson’s Disease Drug Clinical Trial: Research Phase
8.1 Overview
8.2 Clinical Pipeline Insight


9. Global Parkinson’s Disease Drug Clinical Trial: Preclinical Phase
9.1 Overview
9.2 Clinical Pipeline Insight



10. Global Parkinson’s Disease Drug Clinical Trial: Clinical Phase
10.1 Overview
10.2 Clinical Pipeline Insight


11. Global Parkinson’s Disease Drug Clinical Trial: Phase-I
11.1 Overview
11.2 Clinical Pipeline Insight


12. Global Parkinson’s Disease Drug Clinical Trial: Phase-I/II
12.1 Overview
12.2 Clinical Pipeline Insight


13. Global Parkinson’s Disease Drug Clinical Trial: Phase-II
13.1 Overview
13.2 Clinical Pipeline Insight


14. Global Parkinson’s Disease Drug Clinical Trial: Phase-II/III
14.1 Overview
14.2 Clinical Pipeline Insight


15. Global Parkinson’s Disease Drug Clinical Trial: Phase- III Phase
15.1 Overview
15.2 Clinical Pipeline Insight


16. Global Parkinson’s Disease Drug Clinical Trial: Preregistration Phase
16.1 Overview
16.2 Clinical Pipeline Insight


17. Global Parkinson’s Disease Drug Clinical Trial: Registered Phase
17.1 Overview
17.2 Clinical Pipeline Insight


18. Global Marketed Parkinson’s Drugs Clinical Insight


19. Competitive Landscape
19.1 Novartis
19.2 Merck
19.3 Pfizer
19.4 GlaxoSmithKline plc
19.5 Roche
19.6 Teva Pharmaceuticals
19.7 AbbVie Inc.
19.8 Mylan
19.9 Boehringer Ingelheim
19.10 Orion Pharma
19.11 ACADIA Pharmaceuticals Inc



List of Figures


Figure 1-1: Global – Patients with Parkinson’s Disease (Million), 2016 & 2019
Figure 1-2: Global – Prevalence of Parkinson’s Disease by Age, 2019
Figure 1-3: Global – Parkinson’s Cases by Leading Countries (Million), 2019
Figure 1-4: Global – Parkinson’s Cases by Leading Countries (%), 2019
Figure 1-5: Global – Parkinson’s Prevalence by Gender (%), 2019
Figure 1-6: US – Number of Parkinson’s Patients (Million), 2016, 2020 & 2030
Figure 1-7: US – Age Standardized Parkinson’s Prevalence Rate (Per 100,000 Population), 2019
Figure 1-8: US – Parkinson’s Patients by Leading States, 2019
Figure 1-9: US – Parkinson’s Patients by Gender (Million), 2019
Figure 1-10: US – Total Population v/s Population with 65+ Age (Million), 2019
Figure 1-11: US – Number of Parkinson’s Related Deaths & Incidence, 2017
Figure 1-12: US – Age Standardized Parkinson’s Death Rate (Per 100,000 Peoples), 2017
Figure 1-13: Canada – Age Standardized Parkinson’s Average Prevalence Rate (Per 100,000 Peoples), 2019
Figure 1-14: Canada – Parkinson’s Patients by Gender, 2019
Figure 1-15: Canada – Parkinson’s Disease Related Deaths, 2016 & 2017
Figure 1-16: Canada – Age Standardized Parkinson’s Death Rate by Gender (Per 100,000 Peoples), 2017
Figure 1-17: Canada – Total Population vs Population with 65+ Age (Million), 2019
Figure 1-18: UK – Patients with Parkinson’s Disease, 2015, 2018 & 2025
Figure 1-19: UK – Newly Diagnosed Cases of Parkinson’s Disease, 2015, 2018 & 2025
Figure 1-20: UK – Parkinson’s Patients by Countries, 2018
Figure 1-21: UK – Parkinson’s Patients Share by Countries (%), 2018
Figure 1-22: UK – Newly Diagnosed Parkinson’s Cases by Countries, 2018
Figure 1-23: UK – Parkinson’s Patients by Age, 2018
Figure 1-24: UK – Total Population v/s Population with 65+ Age (Million), 2019
Figure 1-25: UK – Parkinson’s Related Deaths, 2016 & 2017
Figure 1-26: UK – Age Standardized Parkinson’s Death Rate (Per 100,000 Peoples), 2017
Figure 1-27: Germany – Parkinson’s disease Patients, 2016 & 2019
Figure 1-28: Germany – Parkinson’s Patients by Gender, 2019
Figure 1-29: Germany – Total Population v/s Population with 65+ Age (Million), 2019
Figure 1-30: Germany – Parkinson’s related Deaths, 2016 & 2017
Figure 1-31: Germany – Age Standardized Parkinson’s Death Rate by Gender, 2017
Figure 1-32: Russia – Parkinson’s Affected Population, 2016 & 2019
Figure 1-33: Russia – Age Standardized Parkinson’s Prevalence Rate (Per 100,000 Peoples), 2016
Figure 1-34: Russia – Age Standardized Parkinson’s Death Rate (Per 100,000 Peoples), 2017
Figure 1-35: Russia - Total Population v/s Population with 65+ Age (Million), 2019
Figure 1-36: China – Parkinson’s Patients (Million), 2016 & 2019
Figure 1-37: Global – Parkinson’s Cases – China v/s ROW (%), 2019
Figure 1-38: China – Parkinson’s Cases by Gender (Million), 2019
Figure 1-39: China – Average Age Standardized Parkinson’s Prevalence & Incidence Rate (Per 100,000 Peoples), 2019
Figure 1-40: China - Age Standardized Parkinson’s Death Rate (Per 100,000 Peoples), 2017
Figure 1-41: China – Total Population v/s Population over 65+ Age (Million), 2019
Figure 1-42: Japan – Average Age Standard Parkinson’s Prevalence Rate (Per 100,000 Peoples), 2019
Figure 1-43: Japan – Average Age Standard Parkinson’s Incidence Rate (Per 100,000 Peoples), 2019
Figure 1-44: Japan – Parkinson’s Cases & Deaths, 2016
Figure 1-45: Japan – Parkinson’s Related Deaths, 2016 & 2017
Figure 1-46: Japan - Age Standardized Parkinson’s Death Rate (Per 100,000 Peoples), 2017
Figure 1-47: Japan - Total Population v/s Population over 65+ Age (Million), 2019
Figure 1-48: India – Age Standardized Parkinson’s Prevalence & Incidence Rate (Per 100,000 Peoples), 2019
Figure 1-49: India - Parkinson’s Affected Population, 2016 & 2019
Figure 1-50: India - Parkinson’s related Deaths, 2016 & 2017
Figure 1-51: India - Age Standardized Parkinson’s Death Rate by Gender (Per 100,000 Peoples), 2017
Figure 1-52: India - Total Population v/s Population over 65+ Age (Million), 2019
Figure 1-53: South Korea – Parkinson’s Incidence & Deaths, 2016
Figure 1-54: South Korea – Parkinson’s Related Deaths, 2016 & 2017
Figure 1-55: South Korea – Age Standardized Parkinson’s Death Rate by Gender (Per 100,000 peoples), 2017
Figure 1-56: South Korea - Total Population v/s Population over 65+ Age (Million), 2019
Figure 1-57: Australia – Parkinson’s Cases, 2016 & 2018
Figure 1-58: Australia – Age Standardized Parkinson’s Prevalence Rate (Per 100,000 Peoples), 2019
Figure 1-59: Australia – Parkinson’s Related Deaths, 2015, 2016 & 2017
Figure 1-60: Australia – Age Standardized Parkinson’s Death Rate (Per 100,000 Peoples), 2017
Figure 1-61: Australia – Total Population v/s Population with 65+ Age (Million), 2019
Figure 1-62: New Zealand – Parkinson’s Case, 2015, 2017, 2018 & 2022
Figure 1-63: New Zealand – Parkinson’s Cases by Gender, 2017
Figure 1-64: New Zealand – Age Standardized Parkinson’s Death Rate (Per 100,000 Peoples), 2017
Figure 1-65: New Zealand - Total Population v/s Population over 65+ Age (Million), 2019

Figure 2-1: Global – Parkinson’s Drug Market Size (US$ Billion), 2016 - 2018
Figure 2-2: Global - Parkinson’s Drug Market Size (US$ Billion), 2019 - 2025
Figure 2-3: Parkinson’s Drug Market Size – Total v/s Europe (US$ Billion), 2019
Figure 2-4: Parkinson’s Drug Market Share – ROW v/s Europe (%), 2019
Figure 2-5: Parkinson’s Drug Market Size – Total v/s North America (US$ Billion), 2019
Figure 2-6: Parkinson’s Drug Market Share – ROW v/s North America (%), 2019
Figure 2-7: Global - Parkinson’s Drug Market Size by Mechanism (%), 2018

Figure 3-1: Duopa – FDA Approval & Patent Expiration Year
Figure 3-2: Duopa – Price of 700ml, 100ml & 1ml of Duopa 4.3-20mg/ml Suspension (US$), December’2019
Figure 3-3: Duopa – Maximum Daily, Monthly & Annual Treatment Cost for Parkinson’s Treatment (US$), December’2019
Figure 3-4: Duopa – Global Sales Value (US$ Million), 2016, 2017 & 2018
Figure 3-5: Duopa – US Sales Value (US$ Million), 2016, 2017 & 2018
Figure 3-6: Duopa – Quarterly Sales Value (US$ Million), 2019
Figure 3-7: Rytray – Number of Patents Issued in Different Years
Figure 3-8: Rytray – Price for Supply of 240, 100 & Price per Unit of 23.75-95mg, 36.25-145 mg & 48.75-195mg Dose Capsules (US$), December’2019
Figure 3-9: Rytray – Price for Supply of 240, 100 & Price per Unit of 61.25-245mg Dose Capsules (US$), December’2019
Figure 3-10: Rytray – Recommended Initial & Incremented Dose for Treatment Parkinson’s Patient Na?ve to Levodopa Therapy, December’2019
Figure 3-11: Rytray – Global Sales Value (US$ Million), 2017 & 2018
Figure 3-12: Quarterly Sales Value (US$ Million), 2018 & 2019
Figure 3-13: Sinemet – Price of Different Dose Regimen of Sinemet Oral Tablet (US$), December’2019
Figure 3-14: Sinemet – Per Unit Price of Different Dose Regimen of Sinemet Oral Tablet (US$), December’2019
Figure 3-15: Sinemet – Recommended Initial & Maximum Dose (mg/day), December’2019
Figure 3-16: Sinemet – Per Day Treatment cost for Initial & Maximum Dose (US$), December’2019
Figure 3-17: Neupro – Different Patent Issue & Expiration Year
Figure 3-18; Neupro – Price for Supply of 30 Transdermal Films & Price per Unit (US$), December’ 2019
Figure 3-19: Neupro – Initial & Maximum Recommended Dose for Early Stage Parkinson’s (mg/day), December’2019
Figure 3-20: Neupro – Initial & Maximum Recommended Dose for Late Stage Parkinson’s (mg/day), December’2019
Figure 3-21: Neupro – Global Sales (US$ Million), 2017 & 2018
Figure 3-22: Neupro – Global Half Yearly Sales Value (US$ Million), 2018 & 2019
Figure 3-23: Pramipexole – Price for 90 Tablets Supply of Different Doses (US$), December’2019
Figure 3-24: Pramipexole – Price for 90 Extended Release Tablets Supply of Different Doses (US$), December’2019
Figure 3-25: Pramipexole – Recommended Initial & Maintenance Dose Using Immideate Release Tablets (mg/day), December’2019
Figure 3-26: Pramipexole – Recommended Initial & Maintenance Dose Using Extended Release Tablets (mg/day), December’2019
Figure 3-27: Ropinirole – Price for 100 Tablet Supply of Different Doses (US$), December’2019
Figure 3-28: Ropinirole – Price for 500 Tablet Supply of Different Doses (US$), December’2019
Figure 3-29: Ropinirole – Price for 30 Extended Release Tablet Supply of Different Doses (US$), December’2019
Figure 3-30: Ropinirole – Weekly Recommended Dose & Maximum Dose of Immediate Release Tablet (mg Three Times a Day), December’2019
Figure 3-31: Ropinirole – Initial & Maximum Recommended Dose for Extended Release Tablet (mg/day), December’2019
Figure 3-32: Emsam - Price for 30 Patch Supply & Price per Unit of Various Doses of Emsam Transdermal Patches (US$), December’2019
Figure 3-33: Emsam - Monthly & Annual Treatment Cost of Parkinson’s Disease (US$), December’2019
Figure 3-34: Selegiline – Price for 60 Capsule Supply & per Unit Price of 5mg Capsule (US$), December’2019
Figure 3-35: Selegiline – Price for 60 Tablet Supply & per Unit Price of 5mg Tablet (US$), December’2019
Figure 3-36: Selegiline – Annual Treatment Cost using Tablet & Capsule (US$), December’2019
Figure 3-37: Xadago – Patent Issue & Expiration Year
Figure 3-38: Xadago – Price for 30 Tablet Supply & Price per Unit (US$), December’2019
Figure 3-39: Xadago – Recommended Initial & Incremented Dose For Parkinson’s Treatment (mg/day), December’2019
Figure 3-40: Generic Rasagiline – Price for 30 Tablet Supply of 0.5mg & 1mg Tablet (US$), December’2019
Figure 3-41: Azilect - Price for 30 Tablet Supply of 0.5mg & 1mg Tablet (US$), December’2019
Figure 3-42: Recommended Dose for Monotherapy & Adjuvant Therapy in Concomitant Levodopa/ NonLevodopa Patients (mg/day), December’2019
Figure 3-43: Generic Entacapone – Price for 30, 50 & 100 Tablet Supplies 200mg Tablet (US$), December’2019
Figure 3-44: Comtan - Price for 100 Tablet Supply & Price per Unit of 200mg Tablet (US$), December’2019
Figure 3-45: Entacapone – Recommended Initial & Maximum Dose (mg/day), December’2019
Figure 3-46 Entacapone – Treatment Cost per Day Using Generic & Branded Tablet (US$), December’2019
Figure 3-47: Generic Tolcapon – Price for 90 Tablet Supplies & Per Unit Price of 100mg Tablet (US$), December’2019
Figure 3-48: Tasmar - Price for 100 Tablet Supply & per Unit Price of 100mg Tablet (US$), December’2019
Figure 3-49: Tolcapone – Recommended Initial & Maximum Dose (mg/day), December’2019
Figure 3-50: Tolcapone – Treatment Cost per Day Using Generic & Branded Tablet (US$), December’2019
Figure 3-51: Generic Benztropine – Price for 10ml Supply & per Unit Price 1mg/ml Injectable Solution (US$), December’2019
Figure 3-52: Generic Benztropine – Price for 100 Tablet Supplies of 0.5mg, 1mg & 1.5mg Dose (US$), December’2019
Figure 3-53: Cogentin – Price for 10ml Supply & per Unit Price 1mg/ml Injectable Solution (US$), December’2019
Figure 3-54: Benztropine – Recommended Initial Dose & Maximum Dose (mg/day), December’2019
Figure 3-55: Amantidine – Price for 50 Capsules Supply & per Unit Price of 100mg Capsule (US$), December’2019
Figure 3-56: Amantidine – Price for 100 Tablets Supply & per Unit Price of 100mg Tablets (US$), December’2019
Figure 3-57: Amantidine – Price for 473ml, 1000ml Supplies & per Unit Price of 50mg/ml Syrup (US$), December’2019
Figure 3-58: Amantidine – Daily Treatment Cost using Syrup, Tablet & Capsules (US$), December’2019
Figure 3-59: Nourianz – Patent Issue & Expiration Year
Figure 3-60: Nourianz – Price for 90 Tablet Supply & Price per Unit of Oral Tablet (US$), December’2019
Figure 3-61: Nourianz – Recommended Initial & Maintenance Dose (mg/Day), December’2019
Figure 3-62: Nourianz – Maximum Daily, Monthly & Annual Treatment Cost (US$), December’2019
Figure 3-63: Exelon – Price for 30 Transdermal Patch Supply & Price per Unit (US$), December’2019
Figure 3-64: Generic Rivastigmine Transdermal Patch – Price for a Supply of 30 Patches of Dose 4.6mg, 9.5mg & 13.3 mg (US$), December’2019
Figure 3-65: Exelon – Initial & Maintenance Dose for the Treatment of Parkinson’s Disease
Figure 3-66: Exelon – Monthly & Annual Treatment Cost for Treatment of Parkinson’s disease
Figure 3-67: Rivastigmine – Price for a Supply of 60 capsules of Different Doses (US$), December’2019
Figure 3-68: Rivastigmine – Price for Single capsule of Different Doses (US$), December’2019
Figure 3-69: Rivastigmine – Recommended Initial, Maintenance & Incremented Maintenance Dose (mg/Day), December’2019
Figure 4-1: Global Parkinson’s Drug Market Drivers

Figure 5 -1: Challenges for Global Parkinson’s Drug Market

Figure 7-1: Global - Parkinson’s Disease Clinical Pipeline by Phase (Number), 2020
Figure 7-2: Global - Parkinson’s Drug Pipeline by Drug Class (Number), 2020 till 2025
Figure 7-3: Global - Parkinson’s Drug Pipeline by Mechanism Of Action (Number), 2020 till 2025
Figure 7-4: Global - Parkinson’s Drug Pipeline by Formulation (Number), 2020 till 2025
Figure 7-5: Global - Parkinson’s Drug Pipeline country (Number), 2020 till 2025

Figure 8-1: Share of Research Phase in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 9-1: Share of Preclinical Phase in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 10-1: Share of Clinical Phase in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 11-1: Share of Phase-I in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 12-1: Share of Phase I/II in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 13-1: Share of Phase-II in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 14-1: Share of Phase- II/III in Overall Parkinson’s Drug Clinical Pipeline (%)
Figure 15-1: Share of Phase-III in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 16-1: Share of Preregistration Phase in Overall Parkinson’s Drug Clinical Pipeline (%)

Figure 17-1: Share of Registered Phase in Overall Parkinson’s Drug Clinical Pipeline (%)